Daiichi Sankyo and AstraZeneca’s (AZN) supplemental biologics license application for Enhertu in combination with pertuzumab has been accepted and granted priority review in the U.S. for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Burning Rock announces OncoGuide OncoScreen Plus CDx System approval in Japan
- Sophia Genetics expands collaboration with AstraZeneca
- AstraZeneca, Amgen’s Tezspire recommended for approval in EU
- AstraZeneca’s Koselugo has been recommended for approval in EU
- AstraZeneca’s Latest Study on Budesonide-Formoterol: Key Insights for Investors